Ameloblastoma cell lines derived from different subtypes demonstrate distinct developmental patterns in a novel animal experimental model by Fuchigami, Takao et al.
J Appl Oral Sci.
Abstract
Submitted: October 1, 2019
Modification: October 30, 2019
Accepted: November 11, 2019
Ameloblastoma cell lines derived 
from different subtypes demonstrate 
distinct developmental patterns in a 
novel animal experimental model
Objective: Ameloblastoma is a representative odontogenic tumor 
comprising several characteristic invasive forms, and its pathophysiology 
has not been sufficiently elucidated. A stable animal experimental model 
using immortalized cell lines is crucial to explain the factors causing 
differences among the subtypes of ameloblastoma, but this model has 
not yet been disclosed. In this study, a novel animal experimental model 
has been established, using immortalized human ameloblastoma-derived 
cell lines. Methodology: Ameloblastoma cells suspended in Matrigel were 
subcutaneously transplanted into the heads of immunodeficient mice. 
Two immortalized human ameloblastoma cell lines were used: AM-1 cells 
derived from the plexiform type and AM-3 cells derived from the follicular 
type. The tissues were evaluated histologically 30, 60, and 90 days after 
transplantation. Results: Tumor masses formed in all transplanted mice. 
In addition, the tumors formed in each group transplanted with different 
ameloblastoma cells were histologically distinct: the tumors in the group 
transplanted with AM-1 cells were similar to the plexiform type, and those 
in the group transplanted with AM-3-cells were similar to the follicular type. 
Conclusions: A novel, stable animal experimental model of ameloblastoma 
was established using two cell lines derived from different subtypes of 
the tumor. This model can help clarify its pathophysiology and hasten the 
development of new ameloblastoma treatment strategies.
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Introduction
Ameloblastoma is a representative odontogenic 
benign tumor showing aggressive invasion into 
surrounding bones.1 Additionally, this tumor is classified 
into several subtypes with distinct histological invasive 
growth patterns. However, the molecular mechanisms 
governing these characteristics are unclear. Previously, 
gene mutations in BRAF within the MAPK pathway and 
SMO within the non-MAPK pathway in ameloblastoma 
have been identified.2,3 These findings are very important 
to understand ameloblastoma and for the development 
of new molecular targeted therapies. However, the 
pathophysiology of ameloblastoma has not been 
sufficiently elucidated. In particular, ameloblastoma 
demonstrates various histological forms, such as the 
follicular and the plexiform types, but the causal factors 
for these differences remain unknown. The follicular and 
the plexiform types show different expression patterns 
in various aspects, and their properties are thought to 
be fundamentally different from each other.4-6 In past 
studies, AM-1 and AM-3 cells, which are immortalized 
cell lines derived from human ameloblastoma, have 
been chosen to elucidate the molecular mechanism of 
ameloblastoma invasive growth.7,8 The differences in the 
expression of genes such as matrix metalloproteinase 
have also been found, relating cell invasion of AM-1 cells 
to that of AM-3 cells.8
For cancer, a stable animal experimental model 
is indispensable for elucidating the pathology and 
pursuing new treatment strategies. This also applies 
to ameloblastoma, but few studies report animal 
experimental models of ameloblastoma. Zhang, et 
al.9,10 (2009,2010) established an animal experimental 
model of ameloblastoma consisting of subcutaneous 
xenografts, using primary tumor cells and tissues but 
not immortalized cell lines. Currently, no animal models 
of ameloblastoma use immortalized cells. Considering 
the need for experimental stability and reproducibility, 
an animal experimental model using immortalized 
ameloblastoma cell lines might be useful for researchers. 
The expectation is that a stable animal model will be 
particularly helpful for clarifying the factors underlying 
the differences in collective cell migration in the several 
invasive forms of this unique tumor. In this study, a 
novel animal experimental model is established by 
transplanting immortalized human ameloblastoma 




DMEM and Ham’s F-12 media were purchased 
from Nissui Corp. (Tokyo, Japan). Y-27632 was 
purchased from AdooQ Bioscience (Irvine, CA, USA). 
Hydrocortisone and insulin were purchased from Wako 
Pure Chemical (Osaka, Japan). Recombinant human 
EGF was purchased from Invitrogen Corp. (Carlsbad, 
CA, USA). Matrigel was purchased from Corning (New 
York, USA). Isoflurane was purchased from Wako Pure 
Chemical (Osaka, Japan). Rabbit polyclonal anti-GFP 
antibody was purchased from GeneTEX (Irvine, CA, 
USA).
Animals
All animals were maintained and treated according 
to protocols established by the Division of Laboratory 
Animal Science of the Natural Science Center for 
Research and Education of Kagoshima University. The 
5-week-old female BULB-c/nu immunodeficient mice 
used in this study were obtained from CLEA Japan 
(Tokyo, Japan). The mice were maintained under specific 
pathogen-free conditions, with constant temperature 
(around 27°C), and free access to food and water. 
All animal studies were approved by the Division of 
Laboratory Animal Science at the Natural Science Center 
for Research and Education at Kagoshima University 
(# D19008) and are in accordance with the Japanese 
government’s animal protection and management laws.
Cells and cell culture
Two different types of ameloblastoma immortalized 
cell lines were used: AM-1 and AM-3. The AM-1 cells 
were derived from the plexiform type, whereas the 
AM-3 cells were derived from the follicular type.7,8 
Furthermore, green fluorescence protein (GFP) 
expressing lentiviral vectors were constructed and 
transduced into ameloblastoma cells (AM-1 and 
AM-3) to facilitate the detection of these cells, as 
previously described.11 The GFP-labeled AM-1 and AM-3 
ameloblastoma cells were maintained with F-medium 
(DMEM:Ham’s F-12=1:3) containing 5% fetal calf serum 
(FCS), insulin (10 μg/mL), Y27632 (20 μM), recombinant 
human EGF (0.2 μg/mL), adenine HCL (0.3 mg/mL), 
and hydrocortisone (2 μg/mL).
Transplantation
The AM-1 and AM-3 cells expressing GFP were 
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subcutaneously transplanted by injection, using a 23G 
needle, into the heads of immunodeficient mice under 
isoflurane anesthesia (3%) in the clean bench. The mice 
were sacrificed by cervical dislocation 30, 60, and 90 
days after the transplantation, then the head tissues 
were collected. Ameloblastoma cells were transplanted 
in PBS (2×106 cells/100 μl) or Matrigel (2×106 cells/100 
μl). Matrigel was injected without cells as a negative 
control. Thirty-six mice were divided randomly into 
groups of 3 for each evaluation point in each group. 
Antibiotics were not administered.
Hematoxylin and eosin (H&E) staining and 
immunohistochemistry (IHC)
All samples were fixed for 48 hours in 10% formalin. 
Sections (4 μm thick) were prepared from paraffin-
embedded blocks and stained using the EnVision+ 
system (Dako, Glostrup, Denmark) with an anti-GFP 
rabbit polyclonal antibody (1:200 dilution; GTX113617, 
GeneTex, San Antonio, TX, USA). Antigen retrieval 
was performed in a citrate buffer (pH=6.0) in water 
bath (95°C) for 40 minutes. Negative control sections 
were treated in the same manner, without the primary 
antibody, not showing any GFP staining. The morphology 
was evaluated in H&E-stained sections.
Microscopy
Microscopic images were obtained with a conventional 
epifluorescence microscope (BZ-X700, KEYENCE, Tokyo, 
Japan).
Results
The tumor mass formation on the transplantation 
site
No mass formation was observed on the heads 
of the mice transplanted with Matrigel without cells 
(negative control) (Figure 1A), but there were tumor 
mass formations in the mice transplanted with AM-1 and 
AM-3 cells with Matrigel at all time points (Figure 1B and 
C). Moreover, cells transplanted with PBS did not survive 
(data not shown). The tumor size tended to increase 
until the mark of 60 days, after which significant changes 
Figure 1- Images of the heads of mice at each time point: 30, 60, and 90 days. (A) Negative control group: transplanted with Matrigel 
without cells. (B) AM-1 group: transplanted with AM-1 cells with Matrigel. (C) AM-3 group: transplanted with AM-3 cells with Matrigel. 
Yellow arrows indicate the tumor mass
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were not observed. No mice showed any adverse events.
Histological images of each group transplanted 
with different ameloblastoma cells
Ameloblastoma cells derived from different types of 
the tumor were suspended in Matrigel and transplanted 
into mice. In the negative control group, a small mass 
of Matrigel without cells appeared at the transplantation 
site (Figure 2A). In contrast, the engraftment of 
ameloblastoma cells was found in the slides of all 
other mice (Figure 2B and C). In the AM-1 and AM-3 
groups, different histological images were observed. The 
histologically invasive form of the AM-1-transplanted 
group was similar to that of the plexiform type (Figure 
2B), and that of the AM-3-transplanted group was 
similar to the form of the follicular type (Figure 2C). 
Furthermore, cyst formation was observed in the 
transplanted lesions of the AM-1 group but not in those 
of the AM-3 group (Figure 2B).
E va l u a t i o n  o f  G F P  e x p r e s s i o n  b y 
immunohistochemistry to confirm the presence 
of transplanted ameloblastoma cells
The distribution of ameloblastoma cells was 
confirmed by immunohistochemistry (IHC) staining, 
using a GFP antibody. In the negative control group, 
no GFP-positive tumor cells were observed at the 
transplantation site (Figure 3A). In contrast, the tumor 
parenchyma was stained on all slides of ameloblastoma 
cell-transplanted mice (Figure 3B and C). Additionally, 
cellular components around the tumor parenchyma were 
not stained by the GFP antibody (Figure 3B and C).
Discussion
Ameloblastoma is a tumor formed by the proliferation 
of odontogenic-like epithelial cells. The characteristics 
of this tumor are aggressive invasion into surrounding 
tissues and local recurrence.1 Therefore, wide resection 
of the jaw is often performed as part of its treatment.12,13 
However, the pathophysiology of ameloblastoma is still 
reasonably unknown, and new therapeutic methods, 
such as molecular targeted therapy, have not been 
developed. The causal factors of the various histological 
subtypes of ameloblastoma, such as the follicular and 
the plexiform, are particularly difficult to investigate.
AM-1 cells derived from the plexiform type and 
AM-3 cells derived from the follicular type show 
different collective cell invasion patterns in modified 
three-dimensional cultures, as shown previously.11 
Furthermore, the presence of fibroblasts affected the 
invasive form of ameloblastoma cells.13 These findings 
suggest the properties of ameloblastoma cells and 
stromal cells, including fibroblasts around tumor cells, 
may affect the developmental characteristics of tumor 
cells. Three-dimensional culture models are useful for 
studies targeted at specific cells, but it is difficult to 
mimic the actual tumor environment completely with 
such models. Thus, the animal experimental model 
is necessary to solve these problems. In this study, a 
Figure 2- Histological images of H&E staining at each time point: 
30, 60, and 90 days. (A) Negative control group: transplanted 
with Matrigel without cells. (B) AM-1 group: transplanted with 
AM-1 cells with Matrigel. (C) AM-3 group: transplanted with AM-3 
cells with Matrigel. Arrow: Cyst formation at the tumor site in the 
AM-1 group. Lower panels show the areas marked by blue boxes 
in the upper panels. Magnification: Upper panels, 2×; Lower 
panels, 20×
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novel animal experimental model of ameloblastoma was 
established using immortalized cell lines.
A transplant model of ameloblastoma has already 
been reported, Zhang, et al.10 (2010) transplanted 
human ameloblastoma cells under the kidney capsule. 
Moreover, transplantation models for odontogenic 
keratocysts are also reported.14 However, no reports 
were found of an experimental animal model using 
immortalized cell lines of odontogenic tumors. Numerous 
animal experimental models have been reported for 
cancer, including oral cancer, in which tumor cells were 
suspended in PBS or Matrigel for the transplantation. 
In this study, tumor cell engraftment was achieved 
by suspending the cells in Matrigel, a solubilized base 
extracted from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma, which includes laminin, type IV collagen, 
heparin sulfate proteoglycan, entactin/nidogen and 
several growth factors. This product is often used 
for cell culture and animal transplantation.15-17 Since 
ameloblastoma cells do not have apparent proliferative 
activity similar to cancer cells, the Matrigel was used 
as a scaffold and as a growth factor assistant besides 
transplantation.
In this study, an experimental model that is stable, 
simple, and reproducible for ameloblastoma studies 
was created. Furthermore, the transplantation of 
ameloblastoma cells at a site adjacent to the skull 
is beneficial for evaluating tumor-dependent effects 
on bone. There are reports that ameloblastoma cells 
promote osteoclast differentiation,8,18 and the expression 
of bone remodeling markers varies depending on the 
histological type.19 Hence, the effects of ameloblastoma 
cells on bone have to be studied in animal models.
In this study, only ameloblastoma cells were 
transplanted. It is not currently possible to evaluate 
the influence of stromal cells around tumors. Therefore, 
the simultaneous transplantation of ameloblastoma 
cells and stromal cells, such as fibroblasts and bone 
marrow cells, is yet to be performed in further studies. 
In addition, cellular components around the tumor 
Figure 3- Histological images of the immunohistochemistry using the GFP antibody at each time point: 30, 60, and 90 days. (A) Negative 
control group: transplanted with Matrigel without cells. (B) AM-1 group: transplanted with AM-1 cells with Matrigel. (C) AM-3 group: 
transplanted with AM-3 cells with Matrigel. Magnification: 20×
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parenchyma were not stained by IHC staining for 
GFP. These cellular components probably were not 
transformed by ameloblastoma cells but they might have 
migrated from the surroundings of engrafted tumors. 
Originally, ameloblastoma is a tumor formed in the 
jaw, and the environment of the bone marrow might 
influence its development. Even in other tumors, the 
bone marrow environment has been reported to play 
an important role in tumor development.20 In this study, 
ameloblastoma cells were subcutaneously transplanted 
into the heads of mice. A limitation of this study is that 
the experimental environment is very different from the 
actual developmental environment of ameloblastoma. 
Therefore, to investigate the behavior of ameloblastoma 
cells in the bone, using larger animal species, such as 
dogs, is necessary. 
The follicular type and the plexiform type are 
representative histological subtypes of ameloblastoma, 
classified according to the structure of the tumor 
stroma. Some reports indicate that the follicular 
type has a higher recurrence rate than the plexiform 
type,13 but others indicate no clinically significant 
difference.21 In the 4th edition of the WHO classification, 
in 2017, the difference in organization type is not 
regarded as important.22 However, the causal factors 
for the various histological types have not yet been 
elucidated, so it is suggested that these factors should 
be more adequately investigated. In this study, human 
ameloblastoma immortalized cell lines derived from 
two different types were successfully transplanted and 
engrafted into immunodeficient mice. Using this animal 
model of different types of ameloblastoma, previously 
unknown factors concerning the characteristics of 
ameloblastoma can be investigated, and these findings 
may provide important insight into the pathophysiology 
of ameloblastoma.
Conclusion
In conclusion, a novel animal experimental model 
of ameloblastoma was established, using two cell lines 
derived from different subtypes of ameloblastoma. 
The histological images of the group transplanted with 
different ameloblastoma cells were similar to each 
origin. This animal model might help to clarify the factors 
affecting various forms of ameloblastoma invasion in 
the future.
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